Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine, Docetaxel, and Doxorubicin for Uterine Leiomyosarcoma
NCT01533207Phase 3Terminated
- Sponsor
- GOG Foundation
- Start
- Jun 2012
- Primary completion
- Jun 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 8
01
Overview
A Phase 3 trial of gemcitabine, docetaxel, pegylated liposomal doxorubicin in uterine leiomyosarcoma (uLMS), sponsored by GOG Foundation. Started Jun 2012; status: terminated.
02
Drugs
gemcitabinedocetaxelpegylated liposomal doxorubicin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT01533207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01533207.